https://allsci.com/news/clinical-trials/skb378-phase-iii-asthma-skb378win378-advances-to/ AllScien 2026-09-08T17:14:23.611179Z Windward’s TSLP mAb shows six-month asthma activity after single dose https://allsci.com/news/regulatory/crispr-therapy-hereditary-angioedema-fda-grants/ AllScien 2026-09-08T16:53:04.566436Z Intellia’s one-shot CRISPR therapy gets March 2027 FDA decision date https://allsci.com/news/clinical-trials/arlocabtagene-autoleucel-approval-bristol-myers/ AllScien 2026-09-08T16:45:53.392817Z BMS’s GPRC5D CAR-T clears registrational trial in quadruple-exposed multiple myeloma https://allsci.com/news/clinical-trials/inbrx-106-head-and-neck-cancer-inhibrxs-nearly/ AllScien 2026-09-08T16:33:23.949933Z Inhibrx's OX40 agonist nearly doubles response rate versus Keytruda alone in head and neck cancer https://allsci.com/news/research/ai-protein-rna-delivery-ai-designed-vehicles-from/ AllScien 2026-09-08T16:22:03.222760Z German researchers show AI-designed protein vehicles outperform lipid nanoparticles in RNA delivery https://allsci.com/news/clinical-trials/ziltivekimab-phase-iii-trials-stopped-novo/ AllScien 2026-09-08T16:12:06.916844Z Novo Nordisk scraps two Phase III ziltivekimab trials after ZEUS failure https://allsci.com/news/pipe-financing/colorectal-cancer-immunotherapy-funding/ AllScien 2026-09-08T15:24:09.654593Z PDS Biotech raises up to USD 22.55m to advance IL-12 immunotherapy toward Phase III in CRC https://allsci.com/news/clinical-trials/tarlatamab-durvalumab-es-sclc-plus-beats/ AllScien 2026-09-08T15:04:18.241149Z Amgen’s tarlatamab delivers Phase III OS win in first-line ES-SCLC maintenance https://allsci.com/news/venture-financing/moonwalk-biosciences-series-b-funding-raises-usd/ AllScien 2026-09-08T14:52:58.710196Z Moonwalk Bio raises USD 70m Series B for adipose-targeted obesity therapies https://allsci.com/news/clinical-trials/tozorakimab-copd-exacerbations-cuts-across-all/ AllScien 2026-09-08T14:46:50.651150Z AZ’s tozorakimab shows Phase III benefit across eosinophil levels in COPD https://allsci.com/news/approvals/etcamah-breast-cancer-fda-approval-approves-to/ AllScien 2026-09-08T14:33:40.203800Z FDA approves AZ’s Etcamah for pre-progression switch in HR+ breast cancer https://allsci.com/news/clinical-trials/pelacarsen-cardiovascular-trial-failure/ AllScien 2026-09-08T14:13:37.996035Z Novartis’s pelacarsen misses Phase III endpoint despite deep Lp(a) lowering https://allsci.com/news/clinical-trials/del-desiran-phase-iii-myotonic-dystrophy/ AllScien 2026-09-08T13:52:10.140652Z Novartis’s Avidity-acquired del-desiran falls short in Phase III DM1 trial https://allsci.com/news/venture-financing/car-t-therapy-pediatric-brain-cancer-brainchild/ AllScien 2026-09-08T13:32:45.098991Z BrainChild Bio raises USD 116m to advance CAR T therapy for pediatric brain cancer